Based on the Becton Dickinson and Company stock forecast from 8 analysts, the average analyst target price for Becton Dickinson and Company is USD 286.38 over the next 12 months. Becton Dickinson and Company’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Becton Dickinson and Company is Slightly Bearish, which is based on 5 positive signals and 8 negative signals. At the last closing, Becton Dickinson and Company’s stock price was USD 237.27. Becton Dickinson and Company’s stock price has changed by +1.13% over the past week, +0.42% over the past month and -9.07% over the last year.
No recent analyst target price found for Becton Dickinson and Company
No recent average analyst rating found for Becton Dickinson and Company
Company Overview Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey. Address: 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880 Read Less
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public world...Read More
Frequently Asked Questions About Becton Dickinson and Company (BDX) Stock
Based on ratings from 8 analysts Becton Dickinson and Company's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 8 buy, sell and hold ratings.
BDX stock's dividend yield is 1.60%.
Our analysis grades BDX stock's dividend yield at C. This means that BDX stock's dividend yield is above 75% of the stocks in the Medical Instruments & Supplies sector in the NYE exchange.
Based on this BDX may be a average dividend stock for its sector.
Based on targets from 8 analysts, the average taret price for BDX is USD 286.38 over the next 12 months. The maximum analyst target price is USD 312 while the minimum anlayst target price is USD 270.
BDX stock's Price/Earning ratio is 47.64.
Our analysis grades BDX stock's Price / Earning ratio at F. This means that BDX stock's Price/Earning ratio is above 60% of the stocks in the Medical Instruments & Supplies sector in the NYE exchange.
Based on this BDX may be a overvalued for its sector.
The last closing price of BDX's stock was USD 237.27.
The most recent market capitalization for BDX is USD 68.58B.
Based on targets from 8 analysts, the average taret price for BDX is projected at USD 286.38 over the next 12 months.
This means that BDX's stock price may go up by +20.70% over the next 12 months.
We can't find any ETFs which contains Becton Dickinson and Company's stock.
As per our most recent records Becton Dickinson and Company has 70,000 Employees.
Becton Dickinson and Company's registered address is 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880.
You can get more information about it from Becton Dickinson and Company's website at https://www.bd.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Becton Dickinson and Company (BDX) Stock
Based on ratings from 8 analysts Becton Dickinson and Company's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 8 buy, sell and hold ratings.
BDX stock's dividend yield is 1.60%.
Our analysis grades BDX stock's dividend yield at C. This means that BDX stock's dividend yield is above 75% of the stocks in the Medical Instruments & Supplies sector in the NYE exchange.
Based on this BDX may be a average dividend stock for its sector.
Based on targets from 8 analysts, the average taret price for BDX is USD 286.38 over the next 12 months. The maximum analyst target price is USD 312 while the minimum anlayst target price is USD 270.
BDX stock's Price/Earning ratio is 47.64.
Our analysis grades BDX stock's Price / Earning ratio at F. This means that BDX stock's Price/Earning ratio is above 60% of the stocks in the Medical Instruments & Supplies sector in the NYE exchange.
Based on this BDX may be a overvalued for its sector.
The last closing price of BDX's stock was USD 237.27.
The most recent market capitalization for BDX is USD 68.58B.
Based on targets from 8 analysts, the average taret price for BDX is projected at USD 286.38 over the next 12 months.
This means that BDX's stock price may go up by +20.70% over the next 12 months.
We can't find any ETFs which contains Becton Dickinson and Company's stock.
As per our most recent records Becton Dickinson and Company has 70,000 Employees.
Becton Dickinson and Company's registered address is 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880.
You can get more information about it from Becton Dickinson and Company's website at https://www.bd.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BDX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
